FDA Approved: PARSABIV — Supplemental Application (Amgen, Inc)

View source ↗

Summary

The FDA approved a supplemental application for Parsabiv (etelcalcetide) from Amgen, updating the product labeling. The action relates to treatment of secondary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

SUPPL AP for PARSABIV (ETELCALCETIDE)